Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 11:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 913 matching trials from the live ClinicalTrials.gov search.
Conditions
Exudative Macular Degeneration, Diabetic Macular Edema
Interventions
Avastin, Lucentis
Drug
Lead sponsor
Vitreo-Retinal Associates, Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
70
States / cities
Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
VV-14295
Genetic
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Erie, Pennsylvania
Conditions
Cystoid Macular Edema
Interventions
Standard Care, nepafenac
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed No phase listed Observational Accepts healthy volunteers Results available

Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration

NCT01115231
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
2
States / cities
Charleston, South Carolina • Houston, Texas
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization
Interventions
ForeseeHome
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Palm Beach Gardens, Florida • Baltimore, Maryland • St Louis, Missouri
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Ranibizumab, Peripheral Laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab (Lucentis), Argon Laser
Drug · Procedure
Lead sponsor
Rocky Mountain Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Home vision monitoring using myVisionTrack®
Device
Lead sponsor
Vital Art and Science Incorporated
Industry
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Age-Related Macular Degeneration, Macular Degeneration
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Conditions
Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration, Wet Age-Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Houston, Texas • The Woodlands, Texas
Conditions
Age Related Macular Degeneration
Interventions
aflibercept 2.0 mg
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Age Related Macular Degeneration
Interventions
Self management program 'Living with Vision Loss'
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
55 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9,261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Low Vision
Interventions
Virtual bioptic magnification with large field of view, Full field magnification with small field of view
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 100 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Age-related Macular Degeneration
Interventions
E10030
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

NCT07330674
Conditions
Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Interventions
ABF-101, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Interventions
Dexamethasone Implant
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mountain View, California
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
9
States / cities
Boynton Beach, Florida • Fort Meyers, Florida • Miami, Florida + 6 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Avacincaptad Pegol, Lucentis
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 19 more